Peptides for Weight Loss: The Complete Guide

What are weight loss peptides?

Weight loss peptides are medications or research compounds that reduce body weight through hormonal signaling pathways. The most clinically validated class is GLP-1 receptor agonists, which mimic the incretin hormones your body naturally produces after eating.

These compounds work primarily by reducing appetite, slowing gastric emptying, and improving metabolic function. Unlike stimulants or thermogenics, they target the hormonal systems that regulate hunger and satiety — addressing a root cause of weight gain rather than masking symptoms.

The field has evolved rapidly since 2021, when semaglutide (Wegovy) became the first GLP-1 approved specifically for weight management. Dual-receptor agonists like tirzepatide followed, and triple-receptor agonists like retatrutide are now in Phase 3 trials.

FDA-approved weight loss peptides

Three peptide-based medications are currently FDA-approved for chronic weight management:

Semaglutide (Wegovy)

Semaglutide is a GLP-1 receptor agonist approved for adults and adolescents 12+ with BMI 30+ (or 27+ with a weight-related comorbidity). Average weight loss: 14.9% over 68 weeks in the STEP 1 trial. Also shown to reduce cardiovascular events by 20% in the SELECT trial.

• Brand names: Wegovy (weight loss), Ozempic (diabetes)
• Dose: 2.4 mg weekly injection (16-20 week titration)
• Key evidence: STEP 1-5, SELECT trial — 10,000+ participants
• Cost: ~$1,300/month without insurance

Tirzepatide (Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces more weight loss than semaglutide. In the SURMOUNT-5 head-to-head trial, tirzepatide 15 mg achieved 20.2% weight loss versus 13.7% with semaglutide 2.4 mg.

• Brand names: Zepbound (weight loss), Mounjaro (diabetes)
• Dose: 15 mg weekly injection (20-24 week titration)
• Key evidence: SURMOUNT 1-5, SURPASS 1-6 — 15,000+ participants
• Cost: ~$1,060/month without insurance

Liraglutide (Saxenda)

Liraglutide is an older GLP-1 agonist requiring daily injection. Average weight loss: 8% over 56 weeks. Largely superseded by weekly semaglutide but remains an option for patients who prefer daily dosing.

• Brand names: Saxenda (weight loss), Victoza (diabetes)
• Dose: 3.0 mg daily injection
• Cost: ~$1,350/month without insurance

Next-generation peptides in clinical trials

Retatrutide (Triple agonist)

Retatrutide activates three receptors (GIP + GLP-1 + glucagon) and showed 24.2% weight loss in Phase 2 — the highest ever reported for any anti-obesity medication. The addition of glucagon receptor activation increases energy expenditure and dramatically reduces liver fat. Phase 3 trials (TRIUMPH program) are ongoing with results expected in 2026-2027.

Survodutide

Survodutide is a dual GLP-1/glucagon agonist (different from tirzepatide which is GIP/GLP-1). Phase 2 showed 19.2% weight loss. Being developed for both obesity and liver disease (MASH/NAFLD).

CagriSema

CagriSema combines semaglutide with cagrilintide (an amylin analog), attacking appetite through two independent hormonal pathways. Phase 3 trials are ongoing.

Research compounds

These compounds are not FDA-approved for weight loss but are available through research channels or compounding pharmacies. Evidence is more limited than for approved medications.

• Tesofensine — Triple monoamine reuptake inhibitor (oral, not injectable). Different mechanism than GLP-1s.
• AOD-9604 — Fragment of growth hormone. Modest evidence for fat metabolism.
• MOTS-c — Mitochondrial peptide with metabolic effects. Very early research.

Head-to-head comparison

For detailed side-by-side comparisons, see our semaglutide vs tirzepatide, semaglutide vs retatrutide, and tirzepatide vs retatrutide comparison pages.

How weight loss peptides work

Most weight loss peptides work through the incretin system — hormones released by the gut after eating that regulate appetite, blood sugar, and metabolism.

GLP-1 pathway: Reduces appetite through hypothalamic signaling, slows gastric emptying (you feel full longer), and enhances insulin secretion. This is how semaglutide, liraglutide, and the GLP-1 component of tirzepatide and retatrutide work.

GIP pathway: Enhances insulin response, improves fat metabolism, and may have direct effects on adipose tissue. Added by tirzepatide and retatrutide on top of GLP-1.

Glucagon pathway: Increases energy expenditure, promotes hepatic fat oxidation, and stimulates thermogenesis. This "burn more" mechanism is unique to retatrutide and survodutide.

The evolution from single (GLP-1) to dual (GIP/GLP-1) to triple (GIP/GLP-1/glucagon) agonism represents increasingly effective metabolic intervention. Each additional receptor targets a complementary pathway, producing additive weight loss effects.

Side effects and safety

All GLP-1-based medications share a similar side effect profile. Gastrointestinal symptoms are the most common:

Rare but serious risks include pancreatitis (0.1-0.2%), gallbladder events (1-2%), and potential thyroid concerns (boxed warning based on rodent studies). These medications should not be used during pregnancy or in people with a personal or family history of medullary thyroid carcinoma.

Lean mass loss is a concern — research shows 25-40% of weight lost is lean mass without resistance training. Read more about GLP-1 medications and muscle loss.

How to choose the right weight loss peptide

The choice depends on several factors:

• Insurance coverage: Check if your plan covers Wegovy or Zepbound. This often decides the choice.
• Weight loss goal: Higher BMI or more aggressive goals may favor tirzepatide over semaglutide.
• GI tolerance: Tirzepatide has lower GI side effect rates than semaglutide in head-to-head data.
• Diabetes status: If you also have type 2 diabetes, both medications improve blood sugar significantly.
• Liver health: Retatrutide and survodutide show the strongest liver fat reduction (when available).
• Daily vs weekly: Most people prefer weekly injection over daily (semaglutide/tirzepatide over liraglutide).

Visit our weight loss goal page for personalized compound recommendations.

Dosing tools and calculators

If you are using research peptides that require reconstitution, we built free tools to help:

• Peptide Dosage Calculator — Calculate syringe units for any peptide dose
• Reconstitution Calculator — Calculate concentration, doses per vial, and days supply
• BAC Water Calculator — Calculate how much bacteriostatic water to buy for your protocol

FAQ

What is the most effective peptide for weight loss?

Based on clinical trial data, retatrutide shows the highest weight loss (24.2% in Phase 2), followed by tirzepatide (20.9% in SURMOUNT-1) and semaglutide (14.9% in STEP 1). However, retatrutide is not yet FDA-approved. Among approved medications, tirzepatide produces the most weight loss.

Are weight loss peptides safe?

FDA-approved GLP-1 medications like semaglutide and tirzepatide have been studied in over 25,000 clinical trial participants with acceptable safety profiles. Common side effects are gastrointestinal (nausea, diarrhea). Rare risks include pancreatitis and gallbladder events. Research-only peptides have less safety data. Always work with a healthcare provider.

Do you need a prescription for weight loss peptides?

FDA-approved medications (semaglutide/Wegovy, tirzepatide/Zepbound, liraglutide/Saxenda) require a prescription. Research peptides like AOD-9604 and tesofensine are not FDA-approved and are available through some compounding pharmacies or research suppliers, though their use is not regulated for weight loss.

How much weight can you lose on peptides?

Weight loss varies by medication and individual. Clinical trial averages: semaglutide 14.9% body weight at 68 weeks, tirzepatide 20.9% at 72 weeks, retatrutide 24.2% at 48 weeks. For a 250-pound person, this ranges from roughly 37 to 60 pounds. Individual results vary significantly.

Do you regain weight after stopping peptides?

Research shows significant weight regain after discontinuing GLP-1 medications. STEP 4 showed two-thirds of lost weight regained within a year of stopping semaglutide. SURMOUNT-4 showed 14% body weight regain after stopping tirzepatide. Most physicians recommend ongoing treatment, similar to managing other chronic conditions.

Sources

1. STEP 1 — Semaglutide for weight management (NEJM, 2021; PMID: 33567185)
2. SURMOUNT-1 — Tirzepatide for obesity (NEJM, 2022; PMID: 35658024)
3. SURMOUNT-5 — Tirzepatide vs semaglutide head-to-head (NEJM, 2024; PMID: 39652484)
4. Retatrutide Phase 2 — Triple agonist for obesity (NEJM, 2023; PMID: 37351564)
5. SELECT — Semaglutide cardiovascular outcomes (NEJM, 2023; PMID: 37952131)
6. SCALE — Liraglutide for weight management (NEJM, 2015; PMID: 26132939)